Aberrant RL2 O-GlcNAc antibody reactivity against serum-IgA1 of patients with colorectal cancer
- 20 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Glycoconjugate Journal
- Vol. 38 (1), 55-65
- https://doi.org/10.1007/s10719-021-09978-8
Abstract
O-GlcNAcylation, a single attachment of N-acetylglucosamine (GlcNAc) on serine and threonine residues, plays important roles in normal and pathobiological states of many diseases. Aberrant expression of O-GlcNAc modification was found in many types of cancer including colorectal cancer (CRC). This modification mainly occurs in nuclear-cytoplasmic proteins; however, it can exist in some extracellular and secretory proteins. In this study, we investigated whether O-GlcNAc-modified proteins are present in serum of patients with CRC. Serum glycoproteins of CRC patients and healthy controls were enriched by wheat germ agglutinin, a glycan binding protein specifically binds to terminal GlcNAc and sialic acid. Two-dimensional gel electrophoresis, RL2 O-GlcNAc immunoblotting, affinity purification, and mass spectrometry were performed. The results showed that RL2 O-GlcNAc antibody predominantly reacted against serum immunoglobulin A1 (IgA1). The levels of RL2-reacted IgA were significantly increased while total IgA were not different in patients with CRC compared to those of healthy controls. Analyses by ion trap mass spectrometry using collision-induced dissociation and electron-transfer dissociation modes revealed one O-linked N-acetylhexosamine modification site at Ser268 located in the heavy constant region of IgA1; unfortunately, it cannot be discriminated whether it was N-acetylglucosamine or N-acetylgalactosamine because of their identical molecular mass. Although failed to demonstrate unequivocally it was O-GlcNAc, these data indicated that serum-IgA had an aberrantly increased reactivity against RL2 O-GlcNAc antibody in CRC patients. This specific glycosylated form of serum-IgA1 will expand the spectrum of aberrant glycosylation which provides valuable information to cancer glycobiology.Keywords
Funding Information
- National Science and Technology Development Agency (P-12-01487)
- Chulabhorn Research Institute (BC-2020-02)
This publication has 26 references indexed in Scilit:
- Discovery and Confirmation of O-GlcNAcylated Proteins in Rat Liver Mitochondria by Combination of Mass Spectrometry and Immunological MethodsPLOS ONE, 2013
- Glycoproteomic Analysis of AntibodiesMolecular & Cellular Proteomics, 2013
- O-Linked-N-acetylglucosamine on extracellular protein domains mediates epithelial cell–matrix interactionsNature Communications, 2011
- Detection and Analysis of Proteins Modified by O‐Linked N‐AcetylglucosamineCurrent Protocols in Molecular Biology, 2011
- Clustered O-Glycans of IgA1Molecular & Cellular Proteomics, 2010
- The wheat germ agglutinin‐fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progressionJournal of Neuroscience Research, 2010
- Alterations in glycosylation as biomarkers for cancer detectionJournal of Clinical Pathology, 2010
- Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteinsNature, 2007
- Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometryCarbohydrate Research, 2004
- The Glycosylation and Structure of Human Serum IgA1, Fab, and Fc Regions and the Role of N-Glycosylation on Fcα Receptor InteractionsJournal of Biological Chemistry, 1998